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Abstract 
Background: Pediatric low-grade glioma [PLGG] is often a chronic progressive disease requiring 
multiple treatments, i.e. surgery, chemotherapy and irradiation. The multi-state model [MSM] allows an 
extended analysis of disease-states, that patients may undergo, incorporating competing risks over the 
course of time.  
Purpose: We studied disease-state-probabilities of the German SIOP-LGG 2004 cohort from the initial 
state “diagnosis” to the final state “death”. Transient “disease-states” incorporated successive surgical and 
non-surgical treatments. We evaluated clinical risk factors for highly progressive disease requiring 
multiple interventions and death. 
Results: We identified 22 states within 1587 patients (median follow-up 6.3 years). For robust statistical 
calculation, we reduced the model to 7 states and eventually to three levels of disease-progressiveness: 
non, low and highly progressive. Five years after diagnosis state-probabilities were: 0.11 no therapy, 0.49 
one and 0.11 two or more surgeries only, 0.19 one and 0.06 two or more non-surgical interventions with 
or without prior surgery. At this time point higher probability for highly progressive disease was found in 
infants (0.30), supratentorial-midline location (0.17) and diffuse astrocytoma WHO-grade II (0.12). 
Neurofibromatosis type-1 patients were most likely not to be treated (0.36) or to have received only 
non-surgical therapy (0.45). Two years after diagnosis 3-year predictions for highly progressive disease 
and death increased with the number of interventions patients underwent in the first 2 years after 
diagnosis. 
Conclusion: In this first MSM analysis we delineated a refined description of PLGG disease course over 
time, identifying three levels of progressiveness. Growth behavior in the first two years predicted future 
progressiveness and death. 
Key words: pediatric low-grade glioma, multi-state model, survival, multiple interventions, chronic progressive 
disease
1. Introduction 
Pediatric low-grade glioma [PLGG] are a 
heterogeneous group of World Health Organization 
[WHO] grade I and II brain tumors1 that represent the 
most frequent solid primary CNS tumors in the 
pediatric age group2. As 10 to 20 year overall survival 








generally favorable2–7. For many patients, a single 
surgical approach is curative7,8. In contrast, a relevant 
number of patients suffer from chronic progressive 
disease9–12 requiring multiple and often multimodal 
interventions3,11. Each adjuvant therapy, even surgical 
therapy-only, harbor a relevant risk for increased 
long-term sequelae such as cognitive deficits, 
blindness, hearing-loss, hormonal disturbance, or 
obesity many years after onset of disease3,13,14. 
Various studies identified clinical risk factors for 
poor event- and progression-free survival after first 
non-surgical treatment such as age < 1 year at 
diagnosis5,15–17, diencephalic syndrome and/or tumor 
dissemination at diagnosis5,16,18, diffuse glioma WHO 
grade II histology5,16,17, location in the supratentorial 
midline [SML]5,17, the diencephalon, the spinal cord or 
the brainstem3, thalamic tumor site15, incomplete 
resection3,15–17 or no surgery3, tumor size > 3 
square-centimeter15,19, and possibly age > 8 years16. 
While these studies focused on first events and 
progression after the first non-surgical treatment, 
clinical outcome and risk factors for multiple 
interventions, i.e. chronic progressive PLGG 
disease-forms, have scarcely been addressed so 
far12,20. 
Classic survival analysis does not discriminate 
competing risks. Event-probability and influence of 
cofactors onto occurrence of one event may be rather 
coarsely estimated when ignoring presence of further 
possible events with the Kaplan-Meier estimator. 
Considering only one start and one endpoint limits 
the depiction of chronic progressive disease with its 
possible necessity for multiple interventions and the 
potentially associated risk for deterioration of quality 
of survival21–24.  
Based on the semiparametric regression model 
described by Cox25, Aalen and Johansen developed a 
model to estimate transition-probabilities between a 
finite number of states of non-homogenous Markov 
chains26. In 1986 Kay27 introduced a method to 
analyze survival-time incorporating disease-states 
and cofactors with a Markov Model. Since then, 
different multi-state model [MSM] types have been 
developed to enable a more detailed analysis of the 
course of chronic diseases and estimations of future 
events28. The recent introduction of easier-to-use 
software such as the R-packages “mstate”29 facilitated 
wider use of MSM analysis in clinical oncology and 
hematology30–33. Apart from one single-center study 
by Zeidner et al.33 with a mixed cohort of 71 pediatric 
and adult patients with chronic myeloid leukemia, 
none of the pediatric cancer diseases have been 
analyzed using this model so far. In the field of 
neuro-oncology the MSM has not been applied at all. 
Yet, the MSM is especially useful for the application to 
chronic disease as it harbors several advantages: (i) It 
allows inclusion of more than 2 time points for 
survival analysis including competing events for 
which patients may be at risk. (ii) It describes 
development of disease over time. (iii) It includes the 
influence of subsequent events and treatment 
interventions at different time points onto the further 
course of disease. (iv) It evaluates more the prognostic 
covariates that may influence different stages of 
disease at different time points24,34–36.  
Due to the protracted disease-evolution, a more 
detailed analysis of PLGG is warranted to delineate 
growth characteristics and dynamic influence of 
multiple and multimodal treatments, i.e. non-primary 
events as a result of chronic progressive disease 
activity. An early identification of patients at risk for 
highly progressive disease requiring multiple 
interventions is essential. This may improve future 
treatment planning and risk estimation for 
progression as well as brain damage at certain 
disease-states24,29,37. PLGG are considered a cohort of 
disease entities characterized by a single canonical 
pathologic activation of the mitogen-activated protein 
kinase [MAPK] signaling pathway by various genetic 
alterations38,39. Unfortunately, as recruiting of patients 
started far before these key molecular findings were 
revealed, molecular information was not available for 
this MSM study. 
So far, only one study with a PLGG-cohort 
incorporated analysis of competing risks but only for 
cause of death4. This is the very first MSM analysis of 
a population-based cohort of PLGG patients. Our aim 
was to provide a unique MSM of patients’ progress 
with transitions to different states beyond the classical 
survival analysis on the base of recent advances in 
PLGG treatment strategy. We expected to delineate a 
more extended and refined course of PLGG disease, to 
verify previously identified subgroups with less 
interventions and superior OS, as well as risk groups 
for highly progressive disease and death. Finally, our 
aim was to enable a predictive model for future 
growth behavior and probability for death 
considering the course of PLGG disease in the first 
two years after diagnosis. We expect the MSM to 
facilitate evidence-based decision making in the 
management of even chronic progressive PLGG in the 
future and serve as an illustrative basis for prognosis 
and outcome when discussing with families. 
2. Patients and Methods 
2.1 Participants cohort 
This multi-state analysis of pediatric patients 
with LGG included 1587 PLGG patients from 
Germany, registered in the International Society of 




Pediatric Oncology – Low-Grade Glioma [SIOP-LGG] 
2004 study. SIOP-LGG 2004 was a prospective, 
multinational intervention-study active from April 1st, 
2004 to March 31st, 2012 for pediatric patients with 
grade I and II gliomas (according the WHO 
classifications of 2000 and 200740,41) aged 18 years and 
younger at diagnosis. If possible, patients received the 
first surgery for tumor resection or diagnostic biopsy 
and were observed thereafter. Patients with 
neurofibromatosis type 1 [NF-1] and 
hypothalamic/visual pathway glioma and children 
without NF-1, whose tumor showed unequivocal 
contiguous involvement of the visual pathways were 
accepted without biopsy. The term “observation” 
included possible further surgical interventions (e.g. 
in case of radiologic progressive disease [PD]). 
Following incomplete resection or radiological 
diagnosis only, observation was recommended as 
long as there was no radiologic tumor growth and the 
patient did not suffer from significant tumor-related 
symptoms. The definition for “surgical intervention” 
in our analysis involved any extent of tumor resection 
as well as diagnostic biopsy, while surgery for other 
reasons, i.e. shunting procedures for reduction of 
increased intracranial pressure, was not included. In 
case of radiologic PD and/or severe or progressive 
clinical symptoms, patients were stratified to receive 
non-surgical intervention, i.e. primary chemotherapy 
[ChT] for children younger than 8 years. For children 
of 8 years and older, radiotherapy [RT] or ChT could 
be applied (physician’s choice). Patients with NF-1 
received standard ChT, i.e. 85 weeks of vincristine 
and carboplatin [VC]. The protocol included 
randomization of standard VC versus an intensified 
regimen with additional etoposide [VCE] for 
non-NF-1 patients. Central review was performed for 
histology and imaging16. After their first treatment, 
patients were followed. In case of further need of 
intervention, i.e. PD or threatening clinical event, 
patients received further surgical or non-surgical 
therapy (ChT or RT) at the discretion of the local 
oncology team. 
2.2 Statistical analysis/Multi-state analysis 
Analyses were done using the statistical software 
R 3.4.242. Categorical data were summarized as 
absolute and relative frequency. Metric data were 
summarized by median, minimum, and maximum. 
Multi-state analysis was performed to analyze the 
probabilities and risk factors for non, low, and highly 
progressive disease requiring multiple interventions 
following diagnosis, as well as to develop a prediction 
model with starting point 2 years after diagnosis. For 
every patient, the outcome of interest was the types of 
intervention over time, differentiated into surgical 
and non-surgical intervention (ChT or RT). 
Accordingly, a Markovian MSM with the 
clock-forward approach and unidirectional arrows 
was used. Time was measured in years from 
diagnosis. Supplemental Figure S1 displays the 
schematic model of possible states and transitions 
used for first data structuring. The sequences of 
observed multiple interventions are summarized in 
Figure 1. For the multi-state analysis, however, a 
coarsened model based on only 7 states was 
considered in which each state was occupied by a 
sufficient number of patients (n ≥ 60). Figure 2 
illustrates this underlying seven-state model. The 
arrows indicate the directions in which transitions 
were possible. At any given point throughout the 
observation period, a patient was classified to be in 
one of 7 states comprising the initial state “diagnosis” 
(state 1), five transient “disease-states” (state 2-6) and 
the absorbing state “death of any cause” (state 7). PLGG 
histology was centrally confirmed and neuroimaging 
was centrally assessed at diagnosis, upon progression, 
and/or following surgical and non-surgical 
interventions. A patient without any adjuvant therapy 
so far, could move from state 1 to 2 and from state 2 to 
3 at the time of the first and second surgery, 
respectively. Third and further surgeries as well as 3rd 
and further adjuvant therapies are not detailed in 
Figure 2 due to small occupation numbers (< 60 
patients per state). At the start of the first adjuvant 
therapy (ChT or RT), patients moved directly from 
state 1, 2, or 3 to state 4. A patient with only one 
adjuvant therapy so far, could move from state 4 to 
state 5 if a surgery followed first adjuvant therapy. At 
the start of a second adjuvant therapy, patients moved 
from state 4 or 5 to state 6. The absorbing state “death 
of any cause” could be reached instantaneously from 
any other state. The multi-state methodology allowed 
us obtaining the probabilities for combinations of 
interventions by defined risk factors during the course 
of time. State-probabilities at certain time points for 
the whole cohort and subgroups with at least 40 
patients per group were obtained from the 
Aalen-Johansen estimate26 calculated by the “mstate” 
R-package29. State-probabilities were based on a 
transition-specific Cox model. For better inter-study 
comparability of our results we chose identical 
classification of subgroups as stated in the preceding 
HIT-LGG 1996 study5 and confirmed in the 
SIOP-LGG 2004 trial for non-NF-1-patients receiving 
ChT16. Cofactors for analysis of state-specific risk 
groups and influences were as follows: age group 
according to age at diagnosis (< 1 year, 1-711/12 years, ≥ 
8 years), sex, main histology, main location, and NF-1 
status.  




We did not analyze subgroups with patient 
numbers below 40 per group, i.e. disseminated tumor, 
oligodendroglioma WHO grade II, oligoastrocytoma 
WHO grade II, Neurofibromatosis type 2 [NF-2] as 
well as Tuberous Sclerosis Complex [TSC]. Moreover, 
we refrained from further state-differentiation, i.e. 
ChT, RT or type of ChT, as stratification for 1st 
adjuvant therapy and physician’s choice on further 
adjuvant treatment would not allow robust statistical 
conclusions of later disease course. 
 
 
Figure 1. Whole multi-state model for PLGG: Complete disease development of whole group of patients with PLGG. Number of states: 22; Number of transitions 
including those to absorbing state “death”: 44; Possible transitions: 56. The numbers in the boxes (states) correspond to the number of patients who had ever reached the 
corresponding state. The numbers in the arrows represent the number of transitions of patients from one state to the other. Number of transitions in the horizontal plane 
correspond to the number in each box to the right of the transition and were not specified for reasons of clarity. The number of transitions to death is not shown for reasons 
of clarity. 
 
Figure 2. Seven-state model for patients with PLGG. Seven-state MSM, used for further calculations. Number of states: 7; Number of transitions: 14. The numbers in the 
boxes (states) correspond to the number of patients who had ever reached the corresponding state. The numbers in the arrows represent the number of transitions of patients 
from one state to the other. Number of transitions in the horizontal plane correspond to the number in each box to the right of the transition and were not specified for reasons 
of clarity. Levels of progressiveness: non-progressive (states 1 and 2), low progressive (states 3 and 4) and highly progressive (states 5 and 6) PLGG. ChT: chemotherapy. RT: 
radiotherapy. 





Figure 3. Disease-state development for whole group of patients from Germany (n=1587) with PLGG. Stacked-plot of disease-state development over first 10 
years after diagnosis for the whole group of patients with PLGG, starting from date of diagnosis. State-probabilities derived from the multi­state model of Figure 2. Exact numbers 
given for state-probabilities at time point 5 years after diagnosis. State 1: no intervention. State 2: first surgery without prior adjuvant therapy. State 3: two or more surgeries 
without prior adjuvant therapy. State 4: first adjuvant therapy. State 5: one or more surgeries after first adjuvant therapy. State 6: two or more adjuvant therapies. State 7: death 
of any cause. Levels of progressiveness: non-progressive (states 1 and 2), low progressive (states 3 and 4), and highly progressive (states 5 and 6) PLGG. 
 
Figure 4. Disease-state development for patients with PLGG by subgroup age-group. Stacked-plot of disease-state development over first 10 years after diagnosis for 
the subgroup age-group, starting from date of diagnosis: (A) Infant-age < 1 year at diagnosis, (B) 1-711/12 years at diagnosis, and (C) ≥ 8 years at diagnosis. State-probabilities derived 
from the multi­state model of Figure 2. Exact numbers given for state-probabilities at time point 5 years after diagnosis. State 1: no intervention. State 2: first surgery without prior 
adjuvant therapy. State 3: two or more surgeries without prior adjuvant therapy. State 4: first adjuvant therapy. State 5: one or more surgeries after first adjuvant therapy. State 
6: two or more adjuvant therapies. State 7: death of any cause. Levels of progressiveness: non-progressive (states 1 and 2), low progressive (states 3 and 4), and highly progressive 
(states 5 and 6) PLGG. 
 
Stacked-plot figures were produced with the 
“mstate” R-package29 and are shown with 
state-probabilities 5 years after diagnosis starting (i) 
from state 1 at time of diagnosis (Figure 3-8) or (ii) 
from different states at 2 years after diagnosis (Figure 
9). The starting point “2 years after diagnosis” was 
chosen from a clinical point of view, since ChT lasts 
approximately 1.6 years and patients who received 




their first adjuvant therapy shortly after diagnosis still 
had the possibility of a state-transition. Figures 4-8 
show the state-probabilities for different subgroups, 
i.e. age group, sex, location, histology and NF-1 status. 
Since median observation time has not yet reached 10 
years, we cropped all figures at 10 years after 
diagnosis. We additionally evaluated clinical risk 
factors that are possibly associated with a higher 
probability to require multiple interventions or more 
intense treatment, i.e. any intervention beyond 
diagnosis and 1st surgery (states 1 and 2). From a 
clinical point of view we graded progressive disease 
by the number of subsequent interventions received 
at the time point of analysis into (i) “non-progressive 
PLGG” (states 1 and 2) (ii) “low progressive PLGG” 
including 1st adjuvant therapy or at least a 2nd surgery 
without prior adjuvant therapy (states 3 and 4) and 
(iii) “highly progressive PLGG” including 
interventions beyond 1st adjuvant therapy (states 5 
and 6). The analysis was considered as exploratory. 
Accordingly, no adjustment for multiple testing was 
done and p-values are not given. 
3. Results 
3.1 Demographic and clinical characteristics of 
cohort 
Table 1 summarizes demographic and clinical 
characteristics of our cohort. We identified 1587 
patients with primary diagnosis PLGG treated in 
Germany from the SIOP-LGG 2004 database and 
followed them up until April 27th, 2016. Median 
follow-up was 6.3 years. Five years after diagnosis, 36 
patients had deceased and 10 tumors had transformed 
to high-grade glioma. Throughout the observation 
time we identified 22 disease states and 44 transitions 
between states, displayed in Figure 1: 
• 1229/236/40/5/1 patients received 1/2/3/4/5 
surgical interventions without prior adjuvant 
therapy, respectively.  
• 475/140/59/20/3 patients received 1/2/3/4/5 
adjuvant therapies with or without prior surgical 
intervention, respectively.  
• 27 transformed to high-grade histology. 
• 55 patients deceased. 
3.2 Multi-state analysis of the whole group of 
patients with PLGG 
Considering only transition-states with at least 
60 patients, we summarized 7 states with 14 
transitions for the final model (Figure 2). Figure 3 
visualizes state-probabilities for the whole group up 
to an observation time of 10 years. Supplemental table 
S2 indicates development of state-probabilities and 
Aalen standard errors [SE] for the first 10 years after 
diagnosis. Five years after diagnosis the highest 
probability for the whole cohort was to have received 
one surgical intervention only (0.49). At this same 
time point probability for 1st adjuvant therapy was 
0.19. We found identical probabilities to have had two 
or more surgical interventions without prior adjuvant 
therapy (0.11), and not to have received any treatment 
at all (0.11). Probability for low progressive PLGG 
(states 3 and 4) was 0.30 and for highly progressive 
PLGG (states 5 and 6) 0.08. Probability for death 5 
years after diagnosis was 0.02. 
 
Table 1. Demographic and clinical characteristics of German 
patients with pediatric low-grade glioma (n=1587) 
 median  (min / max) 
Age at diagnosis [years]  7.60 (0.10 / 17.90) 
Age-group at diagnosis [years] total (n) (%) 
<1 75 (4.7) 
1-711/12 748 (47.1) 
≥ 8 764 (48.1) 
Sex   
Female 740 (46.6) 
Male 847 (53.4) 
Main location at diagnosis   
Cerebral hemispheres 320 (20.2) 
Supratentorial midline 580 (36.6) 
Cerebellum 467 (29.4) 
Caudal brain stem 119 (7.5) 
Spinal cord 56 (3.5) 
Lateral ventricles 44 (2.8) 
Initially disseminated 1 (0.1) 
Main histology at diagnosis   
Pilocytic Astrocytoma WHO I 869 (54.8) 
Diffuse Astrocytoma WHO II 136 (8.6) 
Oligodendroglioma WHO II 4 (0.3) 
Oligoastrocytoma WHO II 8 (0.5) 
Neuronal and mixed neuronal-glial tumors 203 (12.8) 
Low-grade neuroepithelial or glial lesions not 
otherwise specified [LGG-NOS] 
63 (4.0) 
No histology/radiologic diagnosis-only 304 (19.2) 
Neurofibromatosis [NF] status   
NF negative 1352 (85.2) 
NF-1 233 (14.7) 
NF-2 2 (0.1) 
Tuberous sclerosis complex [TSC]   
TSC negative 1561 (98.4) 
TSC positive* 26 (1.6) 
Extent of resection at 1st surgery (n=1283)   
Complete resection 522 (32.9) 
Subtotal resection 138 (8.7) 
Partial resection 360 (22.7) 
Biopsy-only 263 (16.6) 
1587 patients with pediatric low-grade glioma [PLGG] treated in Germany between 
01.04.2004 and 31.03.2012 and followed until 27.04.2016 in the International Society 
of Paediatric Oncology – Low Grade Glioma subcommittee [SIOP-LGG] 2004 
study. The percentage (%) of patients is given in brackets in respect to the whole 
group. * treatment with everolimus for subependymal giant cell astrocytoma in 
TSC patients was not documented, they remained in the observation group. 
 
3.3 Multi-state analysis for probable risk 
factors 
Supplemental table S3 displays 5-year 
state-probability and Aalen SE for clinical subgroups 
with at least 40 PLGG-patients. Figures 4-8 show 




state-probabilities over 10 years after diagnosis for 
these subgroups. We found a higher 
5-year-probability to decease for infants (0.09), 
patients with tumor location in the spinal cord (0.07), 
and astrocytic tumors WHO grade II (0.10).  
  
Figure 5. Disease-state development for patients with PLGG by subgroup sex. Stacked-plot of disease-state development over first 10 years after diagnosis for the 
subgroup sex, starting from date of diagnosis: (A) Male patients and (B) Female patients. State-probabilities derived from the multi­state model of Figure 2. Exact numbers given 
for state-probabilities at time point 5 years after diagnosis. State 1: no intervention. State 2: first surgery without prior adjuvant therapy. State 3: two or more surgeries without 
prior adjuvant therapy. State 4: first adjuvant therapy. State 5: one or more surgeries after first adjuvant therapy. State 6: two or more adjuvant therapies. State 7: death of any 
cause. Levels of progressiveness: non-progressive (states 1 and 2), low progressive (states 3 and 4), and highly progressive (states 5 and 6) PLGG. 
 




Figure 6. Disease-state development for patients with PLGG by subgroup main location. Stacked-plot of disease-state development over first 10 years after diagnosis 
for the subgroup main location, starting from date of diagnosis: (A) Cerebral hemisphere, (B) Supratentorial midline, (C) Cerebellum, (D) Caudal brainstem, (E) Spinal cord, and 
(F) Lateral ventricle. State-probabilities derived from the multi­state model of Figure 2. Exact numbers given for state-probabilities at time point 5 years after diagnosis. State 1: 
no intervention. State 2: first surgery without prior adjuvant therapy. State 3: two or more surgeries without prior adjuvant therapy. State 4: first adjuvant therapy. State 5: one 
or more surgeries after first adjuvant therapy. State 6: two or more adjuvant therapies. State 7: death of any cause. Levels of progressiveness: non-progressive (states 1 and 2), 
low progressive (states 3 and 4), and highly progressive (states 5 and 6) PLGG. 
 
Figure 7. Disease-state development for patients with PLGG by subgroup main histology. Stacked-plot of disease-state development over first 10 years after 
diagnosis for the subgroup main histology, starting from date of diagnosis: (A) Pilocytic astrocytoma WHO grade I, (B) Diffuse astrocytoma WHO grade II, (C) Neuronal and mixed 
neuronal-glial tumors, and (D) Low-grade neuroepithelial or glial lesions not otherwise specified (LGG-NOS). State-probabilities derived from the multi­state model of Figure 2. 
Exact numbers given for state-probabilities at time point 5 years after diagnosis. State 1: no intervention. State 2: first surgery without prior adjuvant therapy. State 3: two or more 
surgeries without prior adjuvant therapy. State 4: first adjuvant therapy. State 5: one or more surgeries after first adjuvant therapy. State 6: two or more adjuvant therapies. State 
7: death of any cause. Levels of progressiveness: non-progressive (states 1 and 2), low progressive (states 3 and 4), and highly progressive (states 5 and 6) PLGG. 
 
The probability to harbor highly progressive 
disease was especially high for infants (0.30) with a 
noticeably higher probability for 2 or more adjuvant 
therapies (0.27). We found no relevant differences in 
state-probability for highly progressive PLGG 
concerning sex. Compared to patients with other 
tumor locations, those with a SML-glioma showed a 
high probability to need one (0.35) or at least two 
adjuvant therapies (0.13) and the highest 
5-year-probability for highly progressive disease 
(0.17). Nevertheless, the probability of patients with a 
SML-PLGG to stay untreated for at least 5 years after 
diagnosis still was 0.22. Concerning histology, 
astrocytic tumors WHO grade II showed the highest 
probability for highly progressive disease (0.12). 
A more favorable course of disease with no 
intervention at all or only one surgical intervention 
(states 1 and 2), i.e. non-progressive PLGG, was found 




for patients older than 1 year at diagnosis (1-711/12 
years: 0.54; ≥ 8 years: 0.69) and for tumor location in 
the cerebral hemispheres (0.77) or the cerebellum 
(0.76). Patients with a tumor in the lateral ventricles 
had the highest probability to stay stable without any 
adjuvant therapy (1.00). Five years after diagnosis 
patients with a tumor of non-astrocytic histology, i.e. 
neuronal and mixed neuronal-glial tumors as well as 
low-grade neuroepithelial or glial lesions not 
otherwise specified [LGG-NOS], had a probability of 
0.75 and 0.69, respectively, to have had at most one 
surgical intervention (states 1 and 2). Still, the latter 
group of patients showed a probability of 0.06 for 2nd 
adjuvant therapy and as well for death. Patients with 
radiologic tumor diagnosis and without histological 
confirmation were most likely to remain observed 
(0.57; state 1) or to receive one adjuvant therapy only 
(0.43, state 4). Sixty-five percent (n=198) of these 
tumors were located in the optic pathways and 58.7% 
(n=178) were patients with NF-1 (data not shown). 
This is reflected by the state-probabilities for NF-1 
patients with main tumor location in the optic 
pathway (n=180; 77.3%; data not shown) not to be 
treated at all (0.36) or to have received only one 
adjuvant therapy (0.45) 5 years after diagnosis.  
3.4 Impact of disease state at 2 years after 
diagnosis upon prognosis for the subsequent 3 
years 
Supplemental table S4 displays 3-year prediction 
and Aalen SE for further disease development for 
patients assessed at 2 years after diagnosis at their 
respective states. Figure 9 displays the corresponding 
state-probabilities with exact numbers for each 
state-probability at the time point 5 years after 
diagnosis. Patients who had received no intervention 
at all or surgical interventions without prior adjuvant 
therapy in the first 2 years after diagnosis (states 1 and 
2) had the lowest probability (0.01-0.02) for highly 
progressive PLGG (states 5 and 6), while this 
5-year-probability increased noticeably for patients 
who had undergone their 1st adjuvant therapy (state 
4) already in the first 2 years after diagnosis (0.25). The 
probability for death increased with the number of 
interventions that a patient had undergone in the first 
2 years after diagnosis.  
4. Discussion 
In this study, we used a MSM to delineate a more 
refined course of PLGG disease in the German 
SIOP-LGG 2004 cohort of 1587 patients from 
diagnosis throughout possible subsequent 
interventions, i.e. surgery, ChT and RT. To our 
knowledge this is the first multi-state analysis in the 
field of neuro-oncology, especially so in PLGG 
disease. With the help of the MSM we were able to 
evaluate the probabilities for the evolution of 7 
predefined states of disease and 3 levels of 
progressiveness – for the whole cohort as well as for 
defined subgroups. Based on the state of disease 2 
years after diagnosis, we generated a prediction 








Figure 8. Disease-state development for patients with PLGG by subgroup neurofibromatosis type 1 [NF-1] status. Stacked-plot of disease-state development over 
first 10 years after diagnosis for the subgroup NF-1 status, starting from date of diagnosis: (A) NF-1 negative and (B) NF-1 positive. State-probabilities derived from the multi­state 
model of Figure 2. Exact numbers given for state-probabilities at time point 5 years after diagnosis. State 1: no intervention. State 2: first surgery without prior adjuvant therapy. 
State 3: two or more surgeries without prior adjuvant therapy. State 4: first adjuvant therapy. State 5: one or more surgeries after first adjuvant therapy. State 6: two or more 
adjuvant therapies. State 7: death of any cause. Levels of progressiveness: non-progressive (states 1 and 2), low progressive (states 3 and 4), and highly progressive (states 5 and 
6) PLGG. 
 
Figure 9. Impact of state at 2 years after diagnosis on prognosis for the following 3 years. Stacked-plot of disease-state development from 2 to 10 years after 
diagnosis for the whole group of patients with PLGG, starting from different states: A) State 1: no intervention, B) State 2: first surgery without prior adjuvant therapy, C) State 
3: two or more surgeries without prior adjuvant therapy, D) State 4: first adjuvant therapy, E) State 5: one or more surgeries after first adjuvant therapy, F) State 6: two or more 
adjuvant therapies. State-probabilities derived from the multi­state model of Figure 2. Exact numbers given for state-probabilities at time point 5 years after diagnosis. State 7: 
death of any cause. Levels of progressiveness: non-progressive (states 1 and 2), low progressive (states 3 and 4), and highly progressive (states 5 and 6) PLGG. 
 
In our cohort the distribution of epidemiological 
characteristics such as sex, age at diagnosis, NF-status, 
tumor site, and histologic subgroups was comparable 
to other recent series5,6,17. Within a follow-up period of 
6.3 years, patients underwent up to 5 surgical 
interventions and/or up to 5 adjuvant therapies, 
resulting into 22 intervention-states with 44 
transitions. 
At 5 years after diagnosis the highest probability 
for patients was either to have received no 
intervention at all (0.11) or one surgical intervention 
only (0.49). A relevant probability was to have 
undergone one adjuvant therapy (0.19) or at least two 
surgical interventions without adjuvant therapy 
(0.11), defined by us as low progressive disease. Still, 
the probability for needing more than one adjuvant 
treatment – defined as highly progressive PLGG – 
was 0.08. In the series of Gnekow et al., 2012 and 
Stokland et al., 2010 the comparable treatment groups 
comprised 1031 patients (n=668 observation arm 
including surgical interventions; n=363 with 
non-surgical intervention) and 639 patients (n=474 
observation arm; n= 165 with non-surgical 
intervention), respectively. Due to the lack of similar 
analyses no direct comparison to treatment and risk 
groups of other cohorts can be made. While risk 
group definitions generally consider time and 
frequency of tumor-related events, in our model 
probabilities assessed by the MSM relate to 
interventions following tumor-related events. 
Nevertheless, we identified subgroups with a higher 
probability for the necessity of more than one 




adjuvant treatment, i.e. infants, tumor location in the 
SML, and patients with astrocytic tumors WHO grade 
II. We also revealed subgroups with fewer 
interventions – indicating a more favorable course of 
disease, i.e. older age (1-711/12 years and ≥ 8 years), 
tumor location in the cerebral hemispheres, the 
cerebellum and the lateral ventricles, histology of 
neuronal and mixed neuronal-glial tumors or 
LGG-NOS, and patients with NF-1. The number of 
necessary interventions could be a surrogate 
parameter for more or less aggressive tumor biology. 
In our cohort of patients with PLGG, the general 
course of disease was favorable with the highest 
probability to have no or only one surgical 
intervention and a low probability for death, i.e. 
non-progressive biology. This corresponds to 
previous findings of classical survival analyses of 
larger patient series reporting excellent OS in the 
range of 90% for various groups of PLGG, that even 
included subgroups with multiple and multimodal 
interventions5,6,8,17,43. 
Still, we found a relevant probability for patients 
with PLGG to suffer from low (0.30) or highly 
progressive PLGG (0.08) 5 years after diagnosis. These 
probabilities indicate the burden of treatment for 
surviving patients. Both surgical interventions with 
the risk of permanent neurological impairment due to 
damage of healthy brain tissue13,14, as well as multiple 
adjuvant treatments with the risk for enhanced 
long-term neurotoxicity3, may lead to significant 
impairment of long-term quality of survival. 
Few studies focus upon relapse or progression 
beyond first adjuvant therapy and efficacy of 
second-line treatment, with either small numbers9–12, 
selected subgroups of PLGGs, i.e. only astrocytoma 
grade I and II3, or surgery-only7. In addition to those 
limitations, results with respect to progression-free 
survival of those reports cannot be compared to 
state-probabilities due to the different concept of the 
MSM integrating the extensive course of disease of a 
large number of patients. The fact that diagnostic 
entities and underlying WHO criteria have changed 
over the last decades further limits comparability of 
our results to former studies.  
The risk and protective factors identified in the 
German SIOP-LGG 2004 cohort when using the MSM 
confirmed the results of the classical clinical survival 
analysis. An impaired prognosis with a higher risk for 
treatment failure and progressive disease was 
reported for infants, location other than cerebellum 
especially the SML, and LGG WHO grade II3–6,15–17.  
In our cohort, patients with a tumor location in 
the SML were characterized by a higher probability 
for more advanced disease states (0.17). Yet, they had 
also a high probability to stay untreated (0.22) within 
5 years after diagnosis. This may reflect two 
subgroups of PLGG located within the visual 
pathway, i.e. on the one hand those associated with 
NF-1 and good prognosis and on the other hand 
sporadic visual-pathway glioma with a more 
aggressive growth behavior17,44,45.  
Patients with a PLGG of neuronal and mixed 
neuronal-glial histology had an excellent prognosis, 
reflected in a low probability for highly progressive 
PLGG (0.04). At the same time, they showed a higher 
probability for either one (0.75) or several (0.12) 
surgical interventions without prior adjuvant therapy. 
This may relate to the distribution pattern of tumor 
location with an easier access for surgery, i.e. mainly 
in the cerebral hemispheres (69%, data not shown) 
and less frequent in the SML (8.4%, data not shown).  
Finally, patients with LGG-NOS were difficult to 
analyze. The heterogeneity and histological 
uncertainty of this mix of PLGGs that do not meet 
clear criteria for histological classification hampered 
elaborating general statements for this group. 
Therefore, molecular biological analyses are urgently 
needed for clarification of these tumor entities and to 
subdivide histological subgroups38,46,47. 
The MSM allowed predicting further outcome 
on the basis of the state of disease at 2 years after 
diagnosis: The more interventions were necessary in 
the first 2 years after diagnosis, the higher was the 
probability for further interventions as well as for 
death.  
This finding might facilitate the assessment and 
estimation of disease course of future patients with 
PLGG and serve as a basis for clinical 
decision-making at different time points of an 
often-chronic disease.  
Limitations 
We acknowledge certain limitations of our 
study. This study was purely explorative. Moreover, 
some subgroups could not be analyzed separately due 
to the small number of patients. We did not include 
extent of resection at 1st surgery into subgroup 
analysis, as from a statistical point of view this is a 
time-dependent variable, with the future extent of 
resection not known at the time of diagnosis. For 
surgical intervention, we did not distinguish between 
therapeutic tumor resection and diagnostic biopsy. 
Due to the protocol’s stratification structure of 
adjuvant therapy and the possibilities for physician’s 
choice of further adjuvant intervention type, i.e. ChT 
or RT, we were not able to analyze influence of type of 
non-surgical intervention onto subsequent disease 
course. We acknowledge that especially the cohort of 
state 4 is inhomogeneous with respect to the variety of 
prior surgical interventions. It included patients who 




received no, one, two or more prior surgeries of 
different extent and at varying time points. For the 
sake of robust statistical analysis, we refrained from 
separating these subgroups further. Nevertheless, 
from a clinical point of view, this state reflects a group 
of patients whose tumor progression was more 
difficult to handle, as the decision for adjuvant 
therapy was made only when PD or threatening 
clinical symptoms could not be controlled with a 
surgical intervention. Due to a different statistical 
design of the MSM as well as to changing treatment 
strategies and WHO criteria over the last decades, our 
results could not be directly compared to other 
clinical studies of PLGG. Finally, as information on 
molecular markers was not available for patients of 
the SIOP-LGG 2004 study we could not include them 
into the histological subgroup analysis. 
Conclusion 
In summary, we illustrated the potentials and 
feasibility of a MSM for PLGG, extending classic 
survival analysis and incorporating different states 
within the course of patients’ disease, especially of 
chronic forms. Our study provides a comprehensive 
and refined picture of the heterogeneity of PLGG, and 
helps to describe the course of disease and treatment 
with respect to epidemiological subgroups over time. 
Our disease-state-probabilities reaffirm risk and 
prognostic factors already described, particularly 
regarding their relation to the risk for multiple 
interventions. The distribution of disease-states 
confirmed the known dichotomy of tumor behavior in 
the SML, i.e. some tumors needing no intervention at 
all, while others requiring multiple treatments. The 
prognostic model developed in this study provides 
the possibility for a better assessment of disease and 
may serve as a tool for clinical decision-making for 
patients with disease progression. Patients with 
non-progressive disease in the first 2 years after 
diagnosis are unlikely to show further need of 
intervention within the next 3 years while patients 
with progressive disease behavior in the first 2 years 
after diagnosis most likely further maintain this 
aggressive biology. 
Further studies with an a priori multi-state 
design including molecular and toxicity data are 
necessary to confirm our findings and enable more 
exact and individualized treatment recommendation 
for less frequent subgroups. To distinguish subgroups 
further and better explain divergent growth behavior, 
biological markers need to be included for future risk 
group analysis38,46 – especially since there is the 
hypothesis of mainly stable molecular genetics in 
PLGG48 that might determine the growth of the 
individual tumor even in the long run. Molecular data 
will be considered and analyzed with a MSM in the 
ongoing LOGGIC Core Bioclinical Databank. 
Novelty and Impact 
First multi-state analysis of a very large 
population-based cohort of pediatric low-grade 
glioma [PLGG]. It extends classical survival analysis 
by considering subsequent and competing events of 
chronic diseases, such as PLGG. Our seven-state 
model delineated a more refined course over time, 
including influence of subsequent events and 
prognostic factors. We identified three levels of 
progressiveness and generated a prediction model for 
PLGG-disease. This unique approach will be 
validated prospectively in the ongoing LOGGIC Core 
Bioclinical Databank. 
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